Humphreys Keith 4

What Happened

• Keith Humphreys, a director of Indivior Pharmaceuticals, was granted 3,722 Restricted Stock Units (RSUs) on January 26, 2026. The grant shows a $0.00 acquisition price because RSUs are a contingent award that convert to common shares upon vesting; no cash was exchanged at grant.

Key Details

• Transaction date: 2026-01-26 (reported on Form 4 filed 2026-01-28). Transaction code: A (award/grant).
• Grant size and price: 3,722 RSUs @ $0.00 (total reported value $0).
• Vesting: Per footnote, each RSU represents the right to one share and vests the day immediately before the issuer's first annual meeting following the grant, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing summary.
• No 10b5-1 plan, tax-withholding sale, or exercise noted in the filing.

Context

• RSU grants are a common form of equity compensation for directors and do not represent an immediate purchase or sale of stock; they provide future share delivery if vesting conditions are met. Such awards are routine compensation and should be viewed as part of governance/remuneration rather than an immediate market sentiment signal.